U.S. AI-driven Diabetic Retinopathy Screening Market (2026 - 2033) Size, Share & Trends Analysis Report By Component (Software, Hardware, Services), By Screening (Autonomous AI Screening, AI-Assisted Screening), By Deployment Mode, By End Use, And Segment Forecasts

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Market Definitions
                        1.2.1. Component Mode Segment
                        1.2.2. Deployment Mode Segment
                        1.2.3. Screening Segment
                        1.2.4. End Use
                    1.3. Information analysis
                        1.3.1. Market formulation & data visualization
                    1.4. Data validation & publishing
                    1.5. Information Procurement
                        1.5.1. Primary Research
                    1.6. Information or Data Analysis
                    1.7. Market Formulation & Validation
                    1.8. Market Model
                    1.9. Total Market: CAGR Calculation
                    1.10. Objectives
                        1.10.1. Objective 1
                        1.10.2. Objective 2
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Snapshot
                    2.3. Competitive Insights Landscape
Chapter 3. U.S. AI-driven Diabetic Retinopathy Screening Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook.
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                        3.2.2. Market restraint analysis
                        3.2.3. Market opportunity analysis
                        3.2.4. Market challenges analysis
                    3.3. AI-driven Diabetic Retinopathy Screening Market Analysis Tools
                        3.3.1. Industry Analysis - Porter’s
                            3.3.1.1. Supplier power
                            3.3.1.2. Buyer power
                            3.3.1.3. Substitution threat
                            3.3.1.4. Threat of new entrant
                            3.3.1.5. Competitive rivalry
                        3.3.2. PESTEL Analysis
                            3.3.2.1. Political landscape
                            3.3.2.2. Technological landscape
                            3.3.2.3. Economic landscape
                            3.3.2.4. Environmental Landscape
                            3.3.2.5. Legal Landscape
                            3.3.2.6. Social Landscape
                    3.4. Case Studies
                    3.5. Technology Overview
Chapter 4. U.S. AI-driven Diabetic Retinopathy Screening Market: Component Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. U.S. AI-driven Diabetic Retinopathy Screening Market Component Movement Analysis
                    4.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
                    4.4. Software
                        4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    4.5. Hardware
                        4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    4.6. Services
                        4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 5. U.S. AI-driven Diabetic Retinopathy Screening Market: Screening Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. U.S. AI-driven Diabetic Retinopathy Screening Market Screening Movement Analysis
                    5.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by Screening, 2021 to 2033 (USD Million)
                    5.4. Autonomous AI Screening
                        5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    5.5. AI-Assisted Screening
                        5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    5.6. Teleophthalmology-Based Screening
                        5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 6. U.S. AI-driven Diabetic Retinopathy Screening Market: Deployment Mode Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. U.S. AI-driven Diabetic Retinopathy Screening Market Deployment Mode Movement Analysis
                    6.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by Deployment Mode, 2021 to 2033 (USD Million)
                    6.4. Cloud-Based
                        6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    6.5. On-Premise
                        6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    6.6. Hybrid
                        6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 7. AI-driven Diabetic Retinopathy Screening Market: End Use Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. U.S. AI-driven Diabetic Retinopathy Screening Market End Use Movement Analysis
                    7.3. U.S. AI-driven Diabetic Retinopathy Screening Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
                    7.4. Hospitals
                        7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    7.5. Ophthalmic Clinics
                        7.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    7.6. Primary Care Settings
                        7.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    7.7. Teleophthalmology Providers
                        7.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
                    7.8. Others
                        7.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Company/Competition Categorization
                    8.2. Strategy Mapping
                    8.3. Company Market Position Analysis, 2025
                    8.4. Company Profiles/Listing
                        8.4.1. Eyenuk, Inc.
                            8.4.1.1. Company overview
                            8.4.1.2. Financial performance
                            8.4.1.3. Product benchmarking
                            8.4.1.4. Strategic initiatives
                        8.4.2. Digital Diagnostics Inc.
                            8.4.2.1. Company overview
                            8.4.2.2. Financial performance
                            8.4.2.3. Product benchmarking
                            8.4.2.4. Strategic initiatives
                        8.4.3. AEYE Health.
                            8.4.3.1. Company overview
                            8.4.3.2. Financial performance
                            8.4.3.3. Product benchmarking
                            8.4.3.4. Strategic initiatives
                        8.4.4. Optomed
                            8.4.4.1. Company overview
                            8.4.4.2. Financial performance
                            8.4.4.3. Product benchmarking
                            8.4.4.4. Strategic initiatives
                        8.4.5. IRIS (Intelligent Retinal Imaging Systems)
                            8.4.5.1. Company overview
                            8.4.5.2. Financial performance
                            8.4.5.3. Product benchmarking
                            8.4.5.4. Strategic initiatives
                        8.4.6. RETINA-AI Health, Inc.
                            8.4.6.1. Company overview
                            8.4.6.2. Financial performance
                            8.4.6.3. Product benchmarking
                            8.4.6.4. Strategic initiatives
                        8.4.7. iCare
                            8.4.7.1. Company overview
                            8.4.7.2. Financial performance
                            8.4.7.3. Product benchmarking
                            8.4.7.4. Strategic initiatives
                        8.4.8. RetinaRisk (by Risk Medical Solutions)
                            8.4.8.1. Company overview
                            8.4.8.2. Financial performance
                            8.4.8.3. Product benchmarking
                            8.4.8.4. Strategic initiatives
                        8.4.9. BeamMed Inc.
                            8.4.9.1. Company overview
                            8.4.9.2. Financial performance
                            8.4.9.3. Product benchmarking
                            8.4.9.4. Strategic initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. AI-driven diabetic retinopathy screening market, by region, 2021 - 2033 (USD Million)
Table 3 U.S. AI-driven diabetic retinopathy screening market, by component, 2021 - 2033 (USD Million)
Table 4 U.S. AI-driven diabetic retinopathy screening market, by deployment mode, 2021 - 2033 (USD Million)
Table 5 U.S. AI-driven diabetic retinopathy screening market, by screening, 2021 - 2033 (USD Million)
Table 6 U.S. AI-driven diabetic retinopathy screening market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Market formulation & validation
Fig. 5 U.S. AI-driven diabetic retinopathy screening market: Market outlook
Fig. 6 U.S. AI-driven diabetic retinopathy screening market: Segment outlook
Fig. 7 U.S. AI-driven diabetic retinopathy screening market: Competitive landscape outlook
Fig. 8 Parent market outlook
Fig. 9 U.S. AI-driven diabetic retinopathy screening market driver impact
Fig. 10 U.S. AI-driven diabetic retinopathy screening market restraint impact
Fig. 11 U.S. AI-driven diabetic retinopathy screening market: Component outlook and key takeaways
Fig. 12 U.S. AI-driven diabetic retinopathy screening market: Component movement analysis
Fig. 13 Software market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 14 Hardware market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 15 Services market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 16 U.S. AI-driven diabetic retinopathy screening market: Screening outlook and key takeaways
Fig. 17 U.S. AI-driven diabetic retinopathy screening market: Screening movement analysis
Fig. 18 Autonomous AI screening market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 19 AI-assisted screening market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 20 Teleophthalmology-based screening market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 21 AI-driven diabetic retinopathy screening market: Deployment mode outlook and key takeaways
Fig. 22 AI-driven diabetic retinopathy screening market: Deployment mode movement analysis
Fig. 23 Cloud-based market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 24 On-premise market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 25 Hybrid market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 26 AI-driven diabetic retinopathy screening market: End use outlook and key takeaways
Fig. 27 AI-driven diabetic retinopathy screening market: End use movement analysis
Fig. 28 Hospitals market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 29 Ophthalmic clinics market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 30 Primary care settings market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 31 Teleophthalmology providers market estimates and forecasts, 2021 - 2033 (USD Million)
Fig. 32 Others market estimates and forecasts, 2021 - 2033 (USD Million)